US FDA rejects Regeneron's Arcalyst sBLA for gout flare prevention
05:34 EDT 1 Aug 2012 | thePharmaLetter
US drugmaker Regeneron Pharmaceuticals (Nasdaq: REGN) says that the US Food and Drug Administration issued a Complete Response Letter for the supplemental biologics license application (sBLA) for Arcalyst (rilonacept) Injection for subcutaneous use f..
Original Article: US FDA rejects Regeneron's Arcalyst sBLA for gout flare prevention
More From BioPortfolio on "US FDA rejects Regeneron's Arcalyst sBLA for gout flare prevention"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
